<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12893397
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     08
    </month>
    <day>
     01
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     08
    </month>
    <day>
     21
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0002-9343
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       115
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2003
       </year>
       <month>
        Aug
       </month>
       <day>
        1
       </day>
      </pubdate>
     </journalissue>
     <title>
      The American journal of medicine
     </title>
     <isoabbreviation>
      Am. J. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia.
    </articletitle>
    <pagination>
     <medlinepgn>
      115-21
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="PURPOSE" nlmcategory="OBJECTIVE">
      Parathyroid hormone-related peptide (PTHrP) is the predominant cause of malignancy-associated hypercalcemia. However, its prognostic utility is unclear. We aimed to determine the prognostic value of serum PTHrP levels in patients who had hypercalcemia associated with malignancy.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      In this prospective case series, we evaluated 76 patients with a diagnosis of cancer and hypercalcemia (serum calcium level &gt;/=10.3 mg/dL on at least two occasions). PTHrP levels &gt;/=1 pmol/L were considered elevated. We used multivariate Cox regression analysis to identify factors associated with mortality.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Fifty patients (66%) died during follow-up. In a multivariate analysis, higher pretreatment calcium levels and elevated PTHrP levels were associated with increased mortality, with effects of PTHrP varying by age (P = 0.03). Survival was associated with pretreatment calcium levels both in patients over 65 years of age (hazard ratio [HR] per mg/dL = 1.5; 95% confidence interval [CI]: 1.2 to 1.8; P &lt;0.001) and in patients aged 65 years or less (HR = 1.3; 95% CI: 1.1 to 1.5; P = 0.003). Adjusted for pretreatment calcium levels, elevated PTHrP levels were associated with increased mortality in patients aged &lt;/=65 years (HR = 3.8; 95% CI: 1.6 to 8.8; P = 0.002), but not in older patients (HR = 0.7; 95% CI: 0.3 to 1.9; P = 0.51).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      PTHrP is a useful prognostic factor in malignancy-associated hypercalcemia, at least in patients aged &lt;/=65 years.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine, Royal Victoria Hospital, Montreal, Canada.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Truong
      </lastname>
      <forename>
       Ngoc Uyen
      </forename>
      <initials>
       NU
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       deB Edwardes
      </lastname>
      <forename>
       Michael D
      </forename>
      <initials>
       MD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Papavasiliou
      </lastname>
      <forename>
       Vasilios
      </forename>
      <initials>
       V
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Goltzman
      </lastname>
      <forename>
       David
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kremer
      </lastname>
      <forename>
       Richard
      </forename>
      <initials>
       R
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Am J Med
    </medlineta>
    <nlmuniqueid>
     0267200
    </nlmuniqueid>
    <issnlinking>
     0002-9343
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Biological Markers
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      PTHLH protein, human
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Parathyroid Hormone-Related Protein
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Peptide Hormones
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Biological Markers
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Comorbidity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypercalcemia
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
     <qualifiername majortopicyn="Y">
      mortality
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Multivariate Analysis
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Neoplasms
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      mortality
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Parathyroid Hormone-Related Protein
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Peptide Hormones
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Predictive Value of Tests
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prognosis
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Reference Values
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Survival Analysis
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      8
     </month>
     <day>
      2
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      8
     </month>
     <day>
      22
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      8
     </month>
     <day>
      2
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12893397
    </articleid>
    <articleid idtype="pii">
     S0002934303003103
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

